The neonatal Fc receptor as therapeutic target in IgG-mediated autoimmune diseases

2010 ◽  
Vol 67 (15) ◽  
pp. 2533-2550 ◽  
Author(s):  
Alina Sesarman ◽  
Gestur Vidarsson ◽  
Cassian Sitaru
Keyword(s):  
Autoimmune Diseases ◽  
Therapeutic Target ◽  
Fc Receptor ◽  
Neonatal Fc Receptor

scholarly journals Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus

2021 ◽  
Author(s):  
Victoria P. Werth ◽  
Donna A. Culton ◽  
Josef S.S. Concha ◽  
James S. Graydon ◽  
Laurence J. Blumberg ◽  
...  
Keyword(s):  
Fc Receptor ◽  
Neonatal Fc Receptor

scholarly journals Immune and non-immune functions of the (not so) neonatal Fc receptor, FcRn

2009 ◽  
Vol 31 (2) ◽  
pp. 223-236 ◽  
Author(s):  
Kristi Baker ◽  
Shuo-Wang Qiao ◽  
Timothy Kuo ◽  
Kanna Kobayashi ◽  
Masaru Yoshida ◽  
...  
Keyword(s):  
Fc Receptor ◽  
Immune Functions ◽  
Neonatal Fc Receptor

Cloning and analysis of the gene encoding the human neonatal Fc receptor

2000 ◽  
Vol 27 (4) ◽  
pp. 231-240 ◽  
Author(s):  
J. E. Mikulska ◽  
L. Pablo ◽  
J. Canel ◽  
N. E. Simister
Keyword(s):  
Fc Receptor ◽  
Neonatal Fc Receptor ◽  
Gene Encoding

Functional Expression of the Human Neonatal Fc-receptor, hFcRn, in Isolated Cultured Human Syncytiotrophoblasts

Placenta ◽  
2009 ◽  
Vol 30 (6) ◽  
pp. 507-515 ◽  
Author(s):  
R. Szlauer ◽  
I. Ellinger ◽  
S. Haider ◽  
L. Saleh ◽  
B.L. Busch ◽  
...  
Keyword(s):  
Functional Expression ◽  
Fc Receptor ◽  
Neonatal Fc Receptor

The neonatal Fc receptor (FcRn) is not required for IVIg or anti-CD44 monoclonal antibody–mediated amelioration of murine immune thrombocytopenia

Blood ◽  
2011 ◽  
Vol 118 (24) ◽  
pp. 6403-6406 ◽  
Author(s):  
Andrew R. Crow ◽  
Sara J. Suppa ◽  
Xi Chen ◽  
Patrick J. Mott ◽  
Alan H. Lazarus
Keyword(s):  
Immune Thrombocytopenia ◽  
Low Dose ◽  
Fc Receptor ◽  
High Dose ◽  
Neonatal Fc Receptor ◽  
Antiplatelet Antibody ◽  
Antibody Treatment ◽  
Acute Itp ◽  
Deficient Mice ◽  
Cd44 Antibody

Abstract To definitively determine whether the neonatal Fc receptor (FcRn) is required for the acute amelioration of immune thrombocytopenia (ITP) by IVIg, we used FcRn-deficient mice in a murine ITP model. Mice injected with antiplatelet antibody in the presence or absence of IVIg displayed no difference in platelet-associated IgG between FcRn deficient versus C57BL/6 mice. FcRn-deficient mice treated with high-dose (2 g/kg) IVIg or a low–dose (2 mg/kg) of an IVIg-mimetic CD44 antibody were, however, protected from thrombocytopenia to an equivalent extent as wild-type mice. To verify and substantiate the results found with FcRn-deficient mice, we used β2-microglobulin–deficient mice (which do not express functional FcRn) and found that IVIg or CD44 antibody also protected them from thrombocytopenia. These data suggest that for both high-dose IVIg as well as low-dose CD44 antibody treatment in an acute ITP model, FcRn expression is neither necessary nor required.

Sign in / Sign up

Export Citation Format

Share Document